Introduction: Tyrosine kinase inhibitors have been a breakthrough in the treatment of advanced medullary thyroid cancer (MTC), and they can prolong progression-free survival (PFS). Case Presentation: A patient with MTC and metastatic spread to the lymph nodes, lungs, bones, breast, and cerebellum started treatment with vandetanib. During treatment, she developed secondary adrenal insufficiency and hypogonadotropic hypogonadism. After 9 years of vandetanib therapy, the disease has not progressed and the patient maintains a complete response of the breast metastases and a partial response of the other metastatic lesions. Conclusion: To our knowledge, this is the first reported case of secondary adrenal insufficiency and hypogonadotropic hypogonadism related to therapy with vandetanib. Moreover, the prolonged PFS and the complete disappearance of some of the metastatic lesions in this patient are truly unusual.
Oncol Res Treat

中文翻译：

---

一个不寻常的垂体功能减退病例作为凡德他尼的不良反应和缓解甲状腺髓样癌患者的乳房转移

简介：酪氨酸激酶抑制剂已成为晚期甲状腺髓样癌（MTC）治疗的突破，可延长无进展生存期（PFS）。病例介绍：一名患有 MTC 并转移至淋巴结、肺、骨骼、乳房和小脑的患者开始使用凡德他尼治疗。在治疗期间，她出现继发性肾上腺功能不全和促性腺激素性性腺功能减退症。经过 9 年的凡德他尼治疗，疾病没有进展，患者保持乳房转移的完全反应和其他转移病灶的部分反应。结论：据我们所知，这是首例报道的与凡德他尼治疗相关的继发性肾上腺功能不全和促性腺功能减退症。此外，该患者延长的 PFS 和一些转移性病变的完全消失确实是不寻常的。
Oncol Res Treat